Tiamenidine
Tiamenidine is an imidazoline compound that shares many of the pharmacological properties of clonidine. It acts as a centrally-acting α1 and α2 adrenergic receptor antagonist. In hypertensive volunteers, like clonidine, it significantly increased sinus node recovery time and lowered cardiac output. It was marketed by Sanofi-Aventis under the brand name Sundralen for the management of essential hypertension.Synthesis
Reaction of thiourea 1 with methyl iodide gives the corresponding S-methyl analogue, followed by heating with ethylenediamine, completes the synthesis of tiamenidine.
